Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 May 1993:
Vol. 260. no. 5112, pp. 1286 - 1293
DOI: 10.1126/science.7684163
Prev | Table of Contents | Next

Articles

Science, Vol 260, Issue 5112, 1286-1293
Copyright © 1993 by American Association for the Advancement of Science

articles

Present status and future prospects for HIV therapies

MI Johnston and DF Hoth

Basic Research and Development Program, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892.

Since the discovery of human immunodeficiency virus (HIV) in 1983, significant progress has been made toward the discovery, development, and licensing of anti-HIV drugs. In vitro screens against whole virus are now being complemented by screens against specific viral targets, resulting in the development of clinical candidates acting at several critical stages of the viral life cycle. Despite these advances, clinical therapy remains largely palliative. In addition, it has recently been recognized that HIV resistance to most drugs may pose even greater obstacles. Moreover, emerging data on immunopathogenesis raise the possibility that even if virus was eliminated from an infected individual, the patient's immune system might not be capable of restoration to normal function. In the face of such obstacles, deeper insights into the pathogenic mechanisms of disease, aggressive exploitation of those mechanisms for therapeutic gain, and continued commitment of both public and private sectors to support and collaborate in this research are needed.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Molecular medicine: promises, promises?.
M. Steel (2005)
J R Soc Med 98, 197-199
   Full Text »    PDF »
Potency of Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) Used in Combination with Other Human Immunodeficiency Virus NNRTIs, NRTIs, or Protease Inhibitors.
R. W. King, R. M. Klabe, C. D. Reid, and S. K. Erickson-Viitanen (2002)
Antimicrob. Agents Chemother. 46, 1640-1646
   Abstract »    Full Text »    PDF »
Probing Interactions between Viral DNA and Human Immunodeficiency Virus Type 1 Integrase Using Dinucleotides.
A. Mazumder, H. Uchida, N. Neamati, S. Sunder, M. Jaworska-Maslanka, E. Wickstrom, F. Zeng, R. A. Jones, R. F. Mandes, H. K. Chenault, et al. (1997)
Mol. Pharmacol. 51, 567-575
   Abstract »    Full Text »
Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy.
C. L. Mackall, T. A. Fleisher, M. R. Brown, M. P. Andrich, C. C. Chen, I. M. Feuerstein, M. E. Horowitz, I. T. Magrath, A. T. Shad, S. M. Steinberg, et al. (1995)
N. Engl. J. Med. 332, 143-149
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)